Pharming Group (OTCMKTS:PHGUF) Sees Large Volume Increase – Should You Buy?

Shares of Pharming Group NV (OTCMKTS:PHGUF) saw strong trading volume on Tuesday . 264,000 shares traded hands during mid-day trading, an increase of 3,499% from the previous session’s volume of 7,336 shares.The stock last traded at $1.20 and had previously closed at $1.28.

Pharming Group Stock Up 1.7%

The company’s 50 day moving average price is $1.47 and its two-hundred day moving average price is $1.62. The company has a current ratio of 2.63, a quick ratio of 2.06 and a debt-to-equity ratio of 0.40. The stock has a market cap of $805.29 million, a P/E ratio of 60.03 and a beta of 0.45.

Pharming Group (OTCMKTS:PHGUF) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.01) earnings per share for the quarter. Pharming Group had a return on equity of 4.64% and a net margin of 3.30%.The business had revenue of $72.45 million during the quarter, compared to the consensus estimate of $92.06 million.

Pharming Group Company Profile

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.